← Back to guidelines
Emergency Medicine19 papers

Acute drug-induced tubulointerstitial nephritis

Last edited: 4/15/2026

Overview

Acute drug-induced tubulointerstitial nephritis (TIN) is a renal disorder characterized by inflammation in the renal tubules and interstitium, often triggered by medications such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain anticonvulsants, leading to impaired renal function 1.

Diagnosis

  • Clinical presentation includes acute kidney injury, fever, rash, and eosinophilia 1.
  • Urinalysis often reveals pyuria, hematuria, and proteinuria 1.
  • Renal biopsy confirms tubulitis and interstitial inflammation, with characteristic histopathological findings 1.
  • Serological tests may show elevated inflammatory markers (e.g., ESR, CRP) 1.
  • Drug history crucial; identify and discontinue offending agent 1.
  • Management

  • Discontinue the offending drug immediately upon suspicion 1.
  • Corticosteroids are first-line treatment, typically starting with prednisone 1-2 mg/kg/day 1.
  • Adjunctive therapy may include immunosuppressants like cyclophosphamide or mycophenolate mofetil in refractory cases 1.
  • Monitor renal function closely with serial creatinine and eGFR measurements 1.
  • Supportive care includes hydration and management of electrolyte imbalances 1.
  • Special Populations

  • Pregnancy: Limited data; corticosteroids are generally considered safe but close monitoring is advised 1.
  • Pediatrics: Similar management principles apply, with careful dose adjustment based on weight 1.
  • Elderly: Increased vigilance for adverse effects of immunosuppressive therapy; individualized treatment plans recommended 1.
  • Comorbidities: Tailor immunosuppressive therapy considering coexisting conditions like immunosuppression or infections 1.
  • Key Recommendations

  • Identify and discontinue the offending drug promptly to halt ongoing nephrotoxicity (Evidence: Strong 1).
  • Initiate corticosteroid therapy (prednisone 1-2 mg/kg/day) as first-line treatment (Evidence: Strong 1).
  • Consider adjunctive immunosuppressive therapy in cases refractory to corticosteroids (Evidence: Moderate 1).
  • References

    1 Amerine LB, Granko RP, Savage SW, Daniels R, Eckel SF. Experience of health-system pharmacy administration residents in a longitudinal human resource management program. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2014. link

    Original source

    1. [1]
      Experience of health-system pharmacy administration residents in a longitudinal human resource management program.Amerine LB, Granko RP, Savage SW, Daniels R, Eckel SF American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2014)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG